VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$41.7m

VYNE Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dave Domzalski

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage23.5%
CEO tenure4yrs
CEO ownership0.2%
Management average tenure4yrs
Board average tenure3yrs

Recent management updates

Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

Dec 08
Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

Recent updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

May 04
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02
Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07
Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

VYNE Therapeutics closes capital raise of $50M

Jan 29

What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?

Jan 06
What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?

VYNE Therapeutics reports successful FDA meeting for FCD105 in acne

Dec 17

Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

Dec 08
Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

CEO Compensation Analysis

How has Dave Domzalski's remuneration changed compared to VYNE Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$3mUS$638k

-US$28m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$638k

-US$34m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$5mUS$638k

-US$44m

Sep 30 2021n/an/a

-US$59m

Jun 30 2021n/an/a

-US$69m

Mar 31 2021n/an/a

-US$226m

Dec 31 2020US$3mUS$501k

-US$256m

Sep 30 2020n/an/a

-US$270m

Jun 30 2020n/an/a

-US$269m

Mar 31 2020n/an/a

-US$120m

Dec 31 2019n/an/a

-US$95m

Sep 30 2019n/an/a

-US$71m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$63m

Dec 31 2018US$1mUS$440k

-US$74m

Sep 30 2018n/an/a

-US$77m

Jun 30 2018n/an/a

-US$80m

Mar 31 2018n/an/a

-US$77m

Dec 31 2017US$3mUS$417k

-US$66m

Compensation vs Market: Dave's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD658.28K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


CEO

Dave Domzalski (56 yo)

4yrs

Tenure

US$2,716,350

Compensation

Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...


Leadership Team

NamePositionTenureCompensationOwnership
David Domzalski
CEO, President & Director4yrsUS$2.72m0.24%
$ 101.0k
Iain Stuart
Chief Scientific Officer4yrsUS$1.16m0.051%
$ 21.2k
Mutya Harsch
General Counsel4yrsUS$1.13m0.15%
$ 62.9k
Tyler Zeronda
CFO & Treasurer2.8yrsno data0.94%
$ 390.2k
Darrell Rigel
Consultant5.3yrsUS$115.20kno data

4.0yrs

Average Tenure

50yo

Average Age

Experienced Management: VYNE's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Domzalski
CEO, President & Director4yrsUS$2.72m0.24%
$ 101.0k
Patrick LePore
Lead Independent Director3.5yrsUS$123.60k0.26%
$ 108.0k
Steven Basta
Director8.5yrsUS$83.60k0.053%
$ 22.1k
Anthony Bruno
Independent Non-Employee Director4yrsUS$101.10k0.013%
$ 5.6k
Elisabeth Sandoval-Little
Independent Director5yrsUS$69.10k0%
$ 0
Christine Borowski
Independent Directorless than a yearno datano data
Sharon Barbari
Independent Non Employee Director4yrsUS$116.10k0.0074%
$ 3.1k
Roy Fleischmann
Member of Scientific Advisory Board2.4yrsno datano data
Martin Okun
Member of Scientific Advisory Board2.4yrsno datano data
David Sachar
Member of Scientific Advisory Board2.4yrsno datano data
Olaf Stuve
Member of Scientific Advisory Board2.4yrsno datano data
Johnathan Whetstine
Member of Scientific Advisory Board2.4yrsno datano data

3.0yrs

Average Tenure

61yo

Average Age

Experienced Board: VYNE's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.